Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.
But not every company with momentum is a long-term winner, and plenty of investors have lost money betting on short-term fads. On that note, here are three stocks that are likely overheated and some you should look into instead.
FormFactor (FORM)
One-Month Return: +19.1%
With customers across the foundry and fabless markets, FormFactor (NASDAQ: FORM) is a US-based provider of test and measurement technologies for semiconductors.
Why Does FORM Worry Us?
- Sales trends were unexciting over the last five years as its 3.8% annual growth was below the typical semiconductor company
- High input costs result in an inferior gross margin of 42.8% that must be offset through higher volumes
- Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital
FormFactor is trading at $136.03 per share, or 40.5x forward P/E. If you’re considering FORM for your portfolio, see our FREE research report to learn more.
Fortrea (FTRE)
One-Month Return: +21.3%
Spun off from Labcorp in 2023 to focus exclusively on clinical research services, Fortrea (NASDAQ: FTRE) is a contract research organization that helps pharmaceutical, biotech, and medical device companies develop and bring their products to market through clinical trials and support services.
Why Do We Pass on FTRE?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 3% annually over the last five years
- Negative returns on capital show that some of its growth strategies have backfired, and its falling returns suggest its earlier profit pools are drying up
- Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions
Fortrea’s stock price of $20.36 implies a valuation ratio of 21.7x forward P/E. To fully understand why you should be careful with FTRE, check out our full research report (it’s free).
Amneal (AMRX)
One-Month Return: +12.6%
Founded in 2002 and growing into one of America's largest generic drug producers, Amneal Pharmaceuticals (NASDAQ: AMRX) develops, manufactures, and distributes generic medicines, specialty branded drugs, biosimilars, and injectable products for the U.S. healthcare market.
Why Do We Think Twice About AMRX?
- Estimated sales growth of 3.3% for the next 12 months implies demand will slow from its two-year trend
- Incremental sales over the last five years were less profitable as its 4.8% annual earnings per share growth lagged its revenue gains
- ROIC of 6.1% reflects management’s challenges in identifying attractive investment opportunities
At $19.43 per share, Amneal trades at 19.6x forward P/E. Read our free research report to see why you should think twice about including AMRX in your portfolio.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
